These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38715057)

  • 1. Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells.
    Zhong P; Nakata K; Oyama K; Higashijima N; Sagara A; Date S; Luo H; Hayashi M; Kubo A; Wu C; He S; Yamamoto T; Koikawa K; Iwamoto C; Abe T; Ikenaga N; Ohuchida K; Morisaki T; Oda Y; Kuba K; Nakamura M
    J Exp Clin Cancer Res; 2024 May; 43(1):138. PubMed ID: 38715057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.
    Zhang Z; Song B; Wei H; Liu Y; Zhang W; Yang Y; Sun B
    Drug Resist Updat; 2024 Mar; 73():101040. PubMed ID: 38228036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
    Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC
    Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.
    Deng Y; Xia X; Zhao Y; Zhao Z; Martinez C; Yin W; Yao J; Hang Q; Wu W; Zhang J; Yu Y; Xia W; Yao F; Zhao D; Sun Y; Ying H; Hung MC; Ma L
    Nat Commun; 2021 Dec; 12(1):7041. PubMed ID: 34873175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
    Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
    Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer.
    Yamamoto K; Venida A; Perera RM; Kimmelman AC
    Autophagy; 2020 Aug; 16(8):1524-1525. PubMed ID: 32459143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ameliorative Effect of Hesperidin Against Motion Sickness by Modulating Histamine and Histamine H1 Receptor Expression.
    Deshetty UM; Tamatam A; Bhattacharjee M; Perumal E; Natarajan G; Khanum F
    Neurochem Res; 2020 Feb; 45(2):371-384. PubMed ID: 31782104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
    Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS
    Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.
    Wouters MM; Balemans D; Van Wanrooy S; Dooley J; Cibert-Goton V; Alpizar YA; Valdez-Morales EE; Nasser Y; Van Veldhoven PP; Vanbrabant W; Van der Merwe S; Mols R; Ghesquière B; Cirillo C; Kortekaas I; Carmeliet P; Peetermans WE; Vermeire S; Rutgeerts P; Augustijns P; Hellings PW; Belmans A; Vanner S; Bulmer DC; Talavera K; Vanden Berghe P; Liston A; Boeckxstaens GE
    Gastroenterology; 2016 Apr; 150(4):875-87.e9. PubMed ID: 26752109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
    Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
    Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative genomic analyses of the histamine H1 receptor and its role in cancer prediction.
    Wang M; Wei X; Shi L; Chen B; Zhao G; Yang H
    Int J Mol Med; 2014 Apr; 33(4):1019-26. PubMed ID: 24535227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.
    Bazhin AV; von Ahn K; Fritz J; Bunge H; Maier C; Isayev O; Neff F; Siveke JT; Karakhanova S
    Oncoimmunology; 2022; 11(1):2043037. PubMed ID: 35251770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade.
    Gu SS; Zhang W; Wang X; Jiang P; Traugh N; Li Z; Meyer C; Stewig B; Xie Y; Bu X; Manos MP; Font-Tello A; Gjini E; Lako A; Lim K; Conway J; Tewari AK; Zeng Z; Sahu AD; Tokheim C; Weirather JL; Fu J; Zhang Y; Kroger B; Liang JH; Cejas P; Freeman GJ; Rodig S; Long HW; Gewurz BE; Hodi FS; Brown M; Liu XS
    Cancer Discov; 2021 Jun; 11(6):1524-1541. PubMed ID: 33589424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer cell migration.
    Park C; Lee JW; Kim K; Seen DS; Jeong JY; Huh WK
    Sci Rep; 2023 Feb; 13(1):1894. PubMed ID: 36732336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer.
    Zhang Y; Chandra V; Riquelme Sanchez E; Dutta P; Quesada PR; Rakoski A; Zoltan M; Arora N; Baydogan S; Horne W; Burks J; Xu H; Hussain P; Wang H; Gupta S; Maitra A; Bailey JM; Moghaddam SJ; Banerjee S; Sahin I; Bhattacharya P; McAllister F
    J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32860704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer.
    Fernández-Nogueira P; Noguera-Castells A; Fuster G; Recalde-Percaz L; Moragas N; López-Plana A; Enreig E; Jauregui P; Carbó N; Almendro V; Gascón P; Bragado P; Mancino M
    Cancer Lett; 2018 Jun; 424():70-83. PubMed ID: 29548821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.
    Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y
    Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.